MedTrace Logo

Eosinophil β1 Integrin Activation as a Biomarker for Eosinophilic Esophagitis

NCT02775045 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 28

Last updated 2019-01-30

No results posted yet for this study

Summary

The purpose of this study is to improve the overall management of patients with Eosinophil Esophagitis. Currently, the best way to monitor Eosinophil Esophagitis is repeating the endoscopy procedure. The investigators plan to identify a biomarker in the blood (a measurable substance) that tracks with disease activity and will reduce the need for follow-up endoscopies.

Conditions

  • Eosinophilic Esophagitis

Interventions

OTHER

Observation Period

8 week observational period

Sponsors & Collaborators

  • National Institutes of Health (NIH)

    collaborator NIH

  • National Institute of Allergy and Infectious Diseases (NIAID)

    collaborator NIH

  • University of Wisconsin, Madison

    lead OTHER

Principal Investigators

  • Sameer Mathur, MD/PhD · UW Madison

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-08-30
Primary Completion
2018-12-13
Completion
2018-12-13

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02775045 on ClinicalTrials.gov